Enhanced Protective Immunity Derived from Dendritic Cells with Phagocytosis of CD40 Ligand Transgene-engineered Apoptotic Tumor Cells via Increased Dendritic Cell Maturation

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate whether dendritic cells loaded with CD40 ligand-engineered apoptotic tumor cells improve dendritic cell maturation and protective antitumor immunity.
Transfected EG7 tumor cells with an adenoviral vector expressing CD40L (EG7-CD40L) or a control vector (EG7-Null).
Induced tumor cell apoptosis via 9,000-rad irradiation and loaded them into dendritic cells via phagocytosis to generate DC-EG7/CD40L and control DC-EG7/Null vaccines.
Evaluated dendritic cell maturation, T-cell responses, and tumor protection following EG7 tumor challenge in C57BL/6 mice.
DC-EG7/CD40L demonstrated increased maturation markers (Ia(b), CD40, CD80, and CD86) and peptide/MHC-I complexes compared to control DC-EG7/Null.
DC-EG7/CD40L vaccines stimulated a higher tumor-specific cytotoxic T-lymphocyte response (0.97%) compared to DC-EG7/Null controls (0.31%).
Immunization with DC-EG7/CD40L resulted in 80% (4/5) tumor-free survival after lethal EG7 challenge, whereas the control vaccine only delayed mortality.

We only have this paper's title and publication details.

Preclinical animal study demonstrates enhanced antitumor immunity in mice, suggesting an improved dendritic cell vaccination strategy.

No takes yet. Share an insight, caveat, or question.

Khalil et al. (2015) studied this question.

View Full Paper

Ask AI

Bookmark

Share